Douglas Tsao

Q: How accurate are Douglas Tsao's stock ratings?

About 48% of Douglas's ratings were profitable over a one-year hold, with an average return of +3.2% per rating, measured by 13Foresight from historical prices.

Q: How is Douglas ranked?

Douglas Tsao is ranked #1720 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#1720

on 13Foresight · ranked by our own returns

48%

Success Rate

+3.2%

Average Return

59 of 124 calls profitable · -86.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 48% of Douglas Tsao's ratings turned a profit when each position was held for 1 year — averaging +3.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

225 Buy 41 Hold 0 Sell

Douglas's Stock Coverage 41 ratings · 2026-10-11

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PCRX Pacira Pharmaceuticals	Oct 09, 2026	HOLD	Hold +8.2% avg upside 23 analysts	$36.50 0.44% Upside	+0.0%	·
ARGX Argenx Se	Oct 08, 2026	BUY	Strong Buy -1.1% avg upside 48 analysts	$1202.00 45.72% Upside	-0.9%	·
PRAX Praxis Precision Medicines	Oct 05, 2026	BUY	Strong Buy +116.7% avg upside 24 analysts	$1201.00 362.09% Upside	-1.9%	·
RZLT Rezolute	Oct 05, 2026	BUY	Strong Buy +141.3% avg upside 14 analysts	$10.00 105.42% Upside	·	·
IMVT Immunovant	Sep 23, 2026	BUY	Buy +32.6% avg upside 25 analysts	$41.00 34.64% Upside	-12.4%	·
RAPP Rapport Therapeutics, Inc.	Sep 23, 2026	BUY	Strong Buy +89.2% avg upside 14 analysts	$66.00 115.35% Upside	-10.2%	·
ALKS Alkermes	Sep 21, 2026	HOLD	Buy +7.8% avg upside 34 analysts	$43.00 5.80% Upside	-9.2%	·
IRON Disc Medicine	Sep 21, 2026	BUY	Strong Buy +42.7% avg upside 21 analysts	$120.00 93.29% Upside	-10.0%	·
CABA Cabaletta Bio	Sep 21, 2026	BUY	Strong Buy +629.4% avg upside 16 analysts	$16.00 729.10% Upside	-21.5%	·
DARE Daré Bioscience	Sep 21, 2026	BUY	Strong Buy +1635.0% avg upside 14 analysts	$12.00 1451.52% Upside	-2.5%	·
CHRS Coherus Biosciences	Sep 21, 2026	BUY	Buy +1056.3% avg upside 18 analysts	$7.00 554.21% Upside	-21.9%	·
XENE Xenon	Sep 18, 2026	BUY	Strong Buy +54.7% avg upside 28 analysts	$74.00 103.03% Upside	-5.5%	·
BHVN Biohaven Ltd.	Sep 10, 2026	HOLD	Buy +88.6% avg upside 25 analysts	$10.00 17.19% Downside	+0.6%	·
ROIV Roivant Sciences	Sep 09, 2026	BUY	Strong Buy +11.9% avg upside 19 analysts	$47.00 32.66% Upside	-15.2%	·
PTGX Protagonist Therapeutics	Sep 01, 2026	BUY	Strong Buy -16.5% avg upside 19 analysts	$170.00 18.25% Upside	-1.9%	·
EOLS Evolus	Aug 25, 2026	BUY	Strong Buy +83.7% avg upside 9 analysts	$13.00 68.08% Upside	-13.9%	·
NMRA Neumora Therapeutics, Inc.	Aug 24, 2026	BUY	Buy +1511.6% avg upside 11 analysts	$7.00 1371.55% Upside	-68.8%	·
AEON AEON Biopharma	Aug 14, 2026	BUY	Strong Buy +503.9% avg upside 3 analysts	$1.20 334.73% Upside	-1.8%	·
ARQT Arcutis Biotherapeutics	Aug 10, 2026	BUY	Strong Buy +51.9% avg upside 14 analysts	$34.00 27.94% Upside	+2.5%	·
NERV Minerva Neurosciences	Aug 10, 2026	HOLD	Strong Buy +162.1% avg upside 8 analysts	$7.00 120.21% Upside	-31.2%	·
VRDN Viridian Therapeutics	Aug 07, 2026	BUY	Strong Buy +88.4% avg upside 32 analysts	$22.00 17.89% Upside	-20.9%	·
OTLK Outlook Therapeutics	Jul 28, 2026	HOLD	Buy +1456.3% avg upside 11 analysts	$1.60 167.16% Upside	-36.7%	·
SE:HNSA Hansa Biopharma AB	Jul 24, 2026	BUY	Strong Buy +290.0% avg upside 4 analysts	$103.00 186.42% Upside	-12.3%	·
EVO Evotec AG	Nov 06, 2025	BUY	Buy +444.5% avg upside 9 analysts	$7.00 357.51% Upside	-53.8%	·
TRVN Trevena	Nov 14, 2024	HOLD	Buy +118650.0% avg upside 11 analysts	$5.00 41566.58% Upside	·	·
RVLPQ RVL Pharmaceuticals	Aug 21, 2023	BUY	Strong Buy +624999900.0% avg upside 6 analysts	$3.00 299999899.93% Upside	·	·
ADOCY Adocia	Apr 21, 2023	HOLD	Hold 1 analyst	—	·	·
CLYM Climb Bio	Mar 08, 2023	HOLD	Strong Buy +99.2% avg upside 20 analysts	$6.00 45.49% Downside	-25.0%	·
TXMD TherapeuticsMD	Nov 30, 2022	HOLD	Buy +203.4% avg upside 8 analysts	—	-43.7%	·
PAHC Phibro Animal Health	Jul 03, 2018	SELL	Hold +1.5% avg upside 10 analysts	$33.00 13.86% Downside	+30.5%	·
TSE:BHC Bausch Health Companies	Jun 06, 2018	BUY	Buy +585.3% avg upside 29 analysts	—	-14.1%	·
PRGO Perrigo Company	Jun 06, 2018	HOLD	Buy +352.9% avg upside 20 analysts	$80.00 431.16% Upside	-39.8%	·
AMRX Amneal Pharmaceuticals	May 01, 2018	BUY	Strong Buy -4.1% avg upside 19 analysts	$27.00 35.56% Upside	-15.6%	·
ZTS Zoetis	Feb 16, 2018	HOLD	Buy +59.5% avg upside 23 analysts	$77.00 2.94% Upside	+20.4%	·
ICLR Icon	Oct 27, 2017	HOLD	Strong Buy +14.4% avg upside 27 analysts	$120.00 26.92% Downside	+14.3%	·
IQV IQVIA Holdings	Oct 27, 2017	BUY	Strong Buy -2.2% avg upside 40 analysts	$120.00 53.74% Downside	+11.6%	·
HALO Halozyme	Jun 22, 2017	BUY	Strong Buy -40.4% avg upside 20 analysts	$16.00 85.52% Downside	+22.0%	·
VTRS Viatris	May 22, 2017	BUY	Buy +34.8% avg upside 22 analysts	$50.00 183.41% Upside	+1.5%	·
JAZZ Jazz Pharmaceuticals	Jan 18, 2017	BUY	Strong Buy +14.7% avg upside 36 analysts	$200.00 8.34% Downside	+16.1%	·
CRL Charles River Labs	Nov 30, 2016	HOLD	Strong Buy -15.5% avg upside 36 analysts	—	+46.6%	·
ARCT Arcturus Therapeutics	Nov 16, 2016	SELL	Buy +123.0% avg upside 36 analysts	$2.00 85.37% Downside	+25.9%	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Douglas Tsao — Frequently Asked Questions

How accurate are Douglas Tsao's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Douglas's ratings were profitable over a one-year hold, with an average return of +3.2% per rating, or -86.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Douglas ranked on 13Foresight?

Douglas Tsao is currently ranked #1720 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Douglas cover?

Douglas most recently has ratings on PCRX, ARGX, PRAX, RZLT, IMVT, RAPP, ALKS, IRON, CABA, DARE, CHRS, XENE and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Douglas Tsao

Rating Distribution

Welcome to 13Foresight!